Joshi, Shruti S https://orcid.org/0000-0001-9874-6211
Singh, Trisha https://orcid.org/0000-0002-4314-9935
Newby, David E https://orcid.org/0000-0001-7971-4628
Singh, Jagdeep
Clinical trials referenced in this document:
Documents that mention this clinical trial
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
https://doi.org/10.1136/heartjnl-2020-318060
Documents that mention this clinical trial
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
https://doi.org/10.1136/heartjnl-2020-318060
Documents that mention this clinical trial
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
https://doi.org/10.1136/heartjnl-2020-318060
Documents that mention this clinical trial
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
https://doi.org/10.1136/heartjnl-2020-318060
Documents that mention this clinical trial
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
https://doi.org/10.1136/heartjnl-2020-318060
Documents that mention this clinical trial
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
https://doi.org/10.1136/heartjnl-2020-318060
Documents that mention this clinical trial
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
https://doi.org/10.1136/heartjnl-2020-318060
Documents that mention this clinical trial
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
https://doi.org/10.1136/heartjnl-2020-318060
Funding for this research was provided by:
AstraZeneca (SJ is also supported by an investigator initiated)
Medical Research Council (TS is supported by MRC CRTF (MR/T029153/1))
Wellcome Trust (DEN is the recipient of a Wellcome Trust Senior In)
British Heart Foundation (DEN is supported by the BHF (CH/09/002, RG/16/10/3)
British Heart Foundation (SJ is supported by a BHF REA fellowship (RE/18/5/3)
British Heart Foundation, Medical Research Council, Wellcome Trust, AstraZeneca (The authors are supported by British Heart Foundation [SJ, RE/18/5/3 and FS/CRTF/20/24087; TS, RE/18/5/3; DEN, CH/09/002, RG/18/5/3), Medical Research Council (TS, MR/T029153/1), Wellcome Trust (DEN, WT103782AIA) and an investigator initiated award from AstraZeneca (SJ, SER-19-20118)])